The pre-clinical to clinical development of these agents in record timeline and regulatory approvals represented a major step for the treatment of these patient populations, not only because of the better overall response rate (ORR) but also because of their better toxicity profile compared with multi-kinase inhibitors previously used in the treatment of RET dependent cancers. This evidence concerns the gene RET and cancer.